BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Papatheodoridi M, Tampaki M, Lok AS, Papatheodoridis GV. Risk of HBV reactivation during therapies for HCC: A systematic review. Hepatology 2022;75:1257-74. [PMID: 34918361 DOI: 10.1002/hep.32241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Zheng Z, Liu Z, Zhang H, Guo X, Jia X, Wang J, Meng L, Xin Y, Jiang X. Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study. Front Pharmacol 2022;13:894016. [PMID: 35656302 DOI: 10.3389/fphar.2022.894016] [Reference Citation Analysis]
2 Sandmann L, Cornberg M. HCC and HBV reactivation-A preventable condition not to be missed. Hepatology 2022;75:1075-7. [PMID: 35007342 DOI: 10.1002/hep.32333] [Reference Citation Analysis]